Lisata Therapeutics (NASDAQ:LSTA) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA) in a report released on Thursday morning,Benzinga reports. The brokerage currently has a $15.00 price objective on the stock.

Lisata Therapeutics Stock Up 1.4 %

LSTA opened at $2.88 on Thursday. The firm has a 50-day moving average price of $2.93 and a 200-day moving average price of $3.09. Lisata Therapeutics has a twelve month low of $2.05 and a twelve month high of $3.83. The company has a market capitalization of $24.18 million, a price-to-earnings ratio of -1.15 and a beta of 1.22.

Lisata Therapeutics (NASDAQ:LSTA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.16. During the same quarter in the prior year, the firm posted ($0.65) EPS. On average, sell-side analysts expect that Lisata Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP increased its position in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 17,336 shares of the company’s stock after acquiring an additional 5,639 shares during the period. Dimensional Fund Advisors LP owned approximately 0.21% of Lisata Therapeutics worth $60,000 as of its most recent filing with the Securities and Exchange Commission. 8.94% of the stock is currently owned by institutional investors and hedge funds.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.